Leave a comment and click here to sub for MS Equity Analysis and Swing Moves.
Good Morning! We hope you all are enjoying your early morning trading! Today, three companies we cover released their schedule 13G form.
What’s a Schedule 13G?
- A document that express a significant change in the ownership of a company
- A more “passive” filing than the 13D
- Tells the shareholders the percentage of the ownership change, and current cap table.
Trevena (Nasdaq: TRVN), Verastem (Nasdaq: VSTM) and Conatus (Nasdaq: CNAT )have all filed a schedule 13G, a precursor to the form 13D, which signifies a change in ownership of over 5% is about to take place. This is huge for these companies as it can cause a potential uptick in the stock’s share price, as well as provide the company with a better use of funding, helping them fund ongoing clinical trials and product development propelling them towards turning a profit. CNAT, VSTM and TRVN are still highly volatile. Institutional ownership bolsters bullish sentiments for a positive long term look, and gives the company more credibility.
- CNAT – BlackRock reveals 5.3% ownership, equating to 1,612,052 shares
- TRVN – Wellington Group Holdings LLP reveals 5.63% ownership, equating to
- VSTM – BlackRock reveals 7.6% ownership, equating to 5,621,011 shares
Want to learn more about CNAT, VSTM and TRVN? Click the links below to find every article we’ve featured them in!
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.